Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | CPT2 | P23786 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15012601 | 1.00 | TDP1 (0.54) | TDP1FFAR1CPT2CYP4F2CYP4A11 | |
| SCHEMBL27628082 | 0.94 | TDP1 (0.48) | TDP1FFAR1CPT2CYP4F2CYP4A11 | |
| SCHEMBL27628076 | 0.94 | TDP1 (0.48) | TDP1FFAR1CPT2CYP4F2CYP4A11 | |
| SCHEMBL19861329 | 0.94 | FFAR1 (0.48) | TDP1FFAR1CPT2CYP4F2CYP4A11 | |
| SCHEMBL20457453 | 0.94 | FFAR1 (0.48) | TDP1FFAR1CPT2CYP4F2CYP4A11 | |
| SCHEMBL27628192 | 0.94 | TDP1 (0.48) | TDP1FFAR1CPT2CYP4F2CYP4A11 | |
| SCHEMBL16305046 | 0.94 | FFAR1 (0.48) | TDP1FFAR1CPT2CYP4F2CYP4A11 | |
| SCHEMBL27608890 | 0.94 | TDP1 (0.48) | TDP1FFAR1CPT2CYP4F2CYP4A11 | |
| SCHEMBL16305049 | 0.94 | FFAR1 (0.48) | TDP1FFAR1CPT2CYP4F2CYP4A11 | |
| SCHEMBL2991062 | 0.93 | FFAR1 (0.68) | TDP1FFAR1CPT2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0081930-B1 | LONG-CHAIN ALPHA, OMEGA-DICARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Epis S.A. (CH) | 1986-07-30 | — | — | EP | claimed |
| EP-0081930-A1 | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Epis S.A. (CH) | 1983-06-22 | — | — | EP | claimed |
| US-10479752-B2 | Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof | SYNDROMEX LTD. (IL) | 2019-11-19 | — | — | US | disclosed |
| EP-2787986-B1 | DEUTERATED TETRAMETHYL DIOIC ACIDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | SYNDROMEX LTD (IL) | 2017-10-18 | — | — | EP | disclosed |
| US-20140371314-A1 | Deuterated Tetramethyl Dioic Acids, Compositions Comprising Them And Uses Thereof | SYNDROMEX LTD. (IL) | 2014-12-18 | — | — | US | disclosed |
| US-20140371314-A1 | Deuterated Tetramethyl Dioic Acids, Compositions Comprising Them And Uses Thereof | SYNDROMEX LTD. (IL) | 2014-12-18 | — | — | US | disclosed |
| EP-2787986-A1 | DEUTERATED TETRAMETHYL DIOIC ACIDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Syndromex Ltd. (IL) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013084237-A1 | DEUTERATED TETRAMETHYL DIOIC ACIDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | SYNDROMEX LTD. (IL) | 2013-06-13 | — | — | WO | disclosed |
| US-7777071-B2 | Production of carnitine conjugate intermediates | SSV THERAPEUTICS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | SSV THERAPEUTICS, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008018877-A1 | CARNITINE CONJUGATES AS DUAL PRODRUGS, METHODS OF PRODUCTION AND USES THEREOF | SSV THERAPEUTICS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2005002557-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ETHER AND SELECTIVE COX-2 INHIBITOR AND USES THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | disclosed |
| WO-2004017952-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| US-4689344-A | ANTICHOLESTEROL AGENTS | EPIS S.A. (CH) | 1987-08-25 | — | — | US | disclosed |
| US-4634795-A | TREATMENT OF OBESITY, HYPERLIPIDEMIA, AND MATURITY-ONSET DIABETES | EPIS S.A. (CH) | 1987-01-06 | — | — | US | disclosed |
| EP-0081930-B1 | LONG-CHAIN ALPHA, OMEGA-DICARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Epis S.A. (CH) | 1986-07-30 | — | — | EP | disclosed |
| EP-0081930-A1 | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Epis S.A. (CH) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | CPT1B, CRAT, CPT2 | TDP1 2577/4885FFAR1 303/4885CPT2 3/4885 |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | TDP1 2229/4885FFAR1 144/4885CPT2 360/4885 |
| US-20140371314-A1 | Deuterated Tetramethyl Dioic Acids, Compositions Comprising Them And Uses Thereof | CYP27A1, GOT2, TXN2 | TDP1 1615/4885FFAR1 515/4885CPT2 44/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | TDP1 4216/4885FFAR1 449/4885CPT2 1268/4885 |
| US-10479752-B2 | Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof | CYP27A1, GOT2, TXN2 | TDP1 1615/4885FFAR1 515/4885CPT2 44/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | TDP1 3787/4885FFAR1 96/4885CPT2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.